ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company developing cancer treatments designed to overcome drug resistance mechanisms. The company's lead candidates include enozertinib, an oral inhibitor targeting specific mutations in EGFR and HER2 genes currently in Phase 1b trials, and rinzimetostat, a polycomb complex inhibitor for prostate cancer also in Phase 1b testing. ORIC has partnered with Bayer and Johnson & Johnson to conduct combination studies of rinzimetostat with their respective prostate cancer therapies.
1Y: 7.86 (-35.8%) · range 7.48–14.65
entry readiness 87 · STRONG SETUP · exit proximity 0
Value area 9.38–14.53 · 95% of 120d volume overhead · heavy supply
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.967 | Nov 13, 2026 |
Not yet labeled — the study prices these as positions mature.